Want to see MDXH full AI Analyst Report?
MDXH Stock Chart & Stats
$0.79
-$0.01(-2.91%)
At close: 4:00 PM EDT
$0.79
-$0.01(-2.91%)
Day’s Range― - ―
52-Week Range$0.40 - $5.33
Previous CloseN/A
Volume391.95K
Average Volume (3M)11.82M
Market Cap
$67.75M
Enterprise Value$107.73
Total Cash (Recent Filing)$29.03M
Total Debt (Recent Filing)$95.11M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Nov 12, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding95,417,380
10 Day Avg. Volume371,108
30 Day Avg. Volume11,815,025
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)-14.77
Price to Sales (P/S)1.66
P/FCF Ratio-15.43
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.50Price Target Upside89.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$111.12M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Commercial MomentumSustained revenue expansion and strong sequential acceleration indicate improving adoption of MDxHealth’s diagnostic portfolio. Reiterated 2026 guidance provides a durable commercial target as the company integrates ExoDx and rebuilds tissue-test volumes.
Healthy Gross Margin And Improving Unit EconomicsA gross margin above 65% suggests the testing model retains attractive underlying economics. Although product mix caused some pressure, strong gross profit growth can support operating leverage as volumes scale and integration costs normalize.
Clinical Evidence And Product DevelopmentPeer-reviewed evidence and continued clinical development strengthen the credibility of MDxHealth’s tests with physicians and health systems. Additional AI capabilities may broaden clinical utility and support longer-term differentiation in molecular diagnostics.
Bears Say
High Leverage And Negative EquityThe sharp increase in debt and negative equity indicate substantial balance-sheet strain. This reduces financial flexibility, increases refinancing and dilution risk, and leaves the company more dependent on successful operating improvement to support obligations.
Persistent Losses And Negative Cash GenerationMDxHealth remains reliant on external capital because operations are not yet self-funding. Continued operating and free-cash-flow losses could constrain investment, increase financing needs, and delay the transition to sustainable profitability despite reduced cash burn.
Reimbursement Disruption And Tissue-Volume WeaknessThe Resolve shutdown shows reimbursement changes can materially disrupt product revenue and customer relationships. Persistent year-over-year tissue weakness also signals execution and competitive pressure, potentially limiting growth and keeping mix-related margin pressure elevated.
MDxHealth News
MDXH FAQ
What was MDxHealth’s price range in the past 12 months?
MDxHealth lowest stock price was $0.40 and its highest was $5.33 in the past 12 months.
What is MDxHealth’s market cap?
MDxHealth’s market cap is $67.75M.
When is MDxHealth’s upcoming earnings report date?
MDxHealth’s upcoming earnings report date is Nov 12, 2026 which is in 69 days.
How were MDxHealth’s earnings last quarter?
MDxHealth released its earnings results on Aug 13, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.193 by $0.013.
Is MDxHealth overvalued?
According to Wall Street analysts MDxHealth’s price is currently Undervalued.
Does MDxHealth pay dividends?
MDxHealth does not currently pay dividends.
What is MDxHealth’s EPS estimate?
MDxHealth’s EPS estimate is -0.09.
How many shares outstanding does MDxHealth have?
MDxHealth has 95,417,380 shares outstanding.
What happened to MDxHealth’s price movement after its last earnings report?
MDxHealth reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.193. Following the earnings report the stock price went up 74.892%.
Which hedge fund is a major shareholder of MDxHealth?
Currently, no hedge funds are holding shares in MDXH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MDxHealth Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.50 (89.87% Upside)
$1.50 (89.87% Upside)
Blogger Sentiment
Neutral
MDXH Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $991.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MDxHealth
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
MDXH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of strong operational and strategic progress — significant sequential revenue acceleration, a successful customer transition, removal of a $10.4M contingent liability, clinical data momentum, and a $20M capital raise — alongside meaningful near-term financial challenges including wider operating and net losses, negative adjusted EBITDA, gross margin compression, and tissue volumes still down year-over-year. Management reiterated full-year revenue guidance ($110M–$115M) and a path to adjusted EBITDA positivity by year-end, striking an overall tone of cautious optimism while acknowledging current profitability headwinds.View all MDXH earnings summariesMDXH Stock 12 Month Forecast
Average Price Target
$1.50
▲(89.87% Upside)
Technical Analysis
Ownership Overview
7.23% Insiders
0.10% Mutual Funds
14.27% Other Institutional Investors
78.25% Public Companies and
Individual Investors